PharoahPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800–809.
RainvilleIRRanaHQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep2014;16:371.
WalshTLeeMKCasadeiS. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A2010;107:12629–12633.
MauerCBPirzadeh-MillerSMRobinsonLDEuhusDM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med2014;16:407–412.
KurianAWHareEEMillsMA. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol2014;32:2001–2009.
TungNBattelliCAllenB. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer2015;121:25–33.
BjorgeTLieAKHovigE. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer2004;91:1829–1834.
JazaeriAALuKSchmandtR. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog2003;36:53–59.
PressJZDe LucaABoydN. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer2008;8:17.
SchraderKAHurlburtJKallogerSE. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol2012;120:235–240.
PalTPermuth-WeyJBettsJA. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer2005;104:2807–2816.
ZhangSRoyerRLiS. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol2011;121:353–357.
RechsteinerMZimmermannAKWildPJ. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol2013;95:235–241.
WernessBARamusSJDiCioccioRA. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol2004;23:29–34.
Ayadi-KaddourABouraouiSBellilK. Colonic adenocarcinoma and bilateral malignant ovarian sex cord tumor with annular tubules in Peutz-Jeghers syndrome. Pathologica2004;96:117–120.
ClementsARobisonKGranaiC. A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. Int J Gynecol Cancer2009;19:1591–1594.
Kondi-PafitiABakalianouKIavazzoC. Endometrial carcinoma and ovarian sex cord tumor with annular tubules in a patient with history of Peutz-Jeghers syndrome and multiple malignancies. Eur J Gynaecol Oncol2011;32:452–454.
LeleSMSawhRNZaharopoulosP. Malignant ovarian sex cord tumor with annular tubules in a patient with Peutz-Jeghers syndrome: a case report. Mod Pathol2000;13:466–470.
KimDHCrawfordBZieglerJBeattieMS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer2009;8:153–158.
LynchHTDetersCASnyderCL. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet2005;158:119–125.
MurphyKMBruneKAGriffinC. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res2002;62:3789–3793.
van AsperenCJBrohetRMMeijers-HeijboerEJ. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet2005;42:711–719.
HolterSBorgidaADoddA. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol2015;33:3124–3129.
LucasALShakyaRLipsycMD. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res2013;19:3396–3403.
StadlerZKSalo-MullenEPatilSM. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer2012;118:493–499.
ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643–651.
TyrerJDuffySWCuzickJ. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med2004;23:1111–1130.
McAlpineJNHanleyGEWooMM. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol2014;210:471.e471–411.
KurmanRJShih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol2011;42:918–931.
PowellCBChenLMMcLennanJ. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer2011;21:846–851.
GreeneMHMaiPLSchwartzPE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?Am J Obstet Gynecol2011;204:19.e11–16.
FindleyADSiedhoffMTHobbsKA. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril2013;100:1704–1708.
SGO Clinical Practice Statement: Salpingectomy for Ovarian Cancer Prevention. Society for Gynecologic Oncology Web site. Available at: https://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/. Accessed May 18 2015.
CallahanMJCrumCPMedeirosF. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol2007;25:3985–3990.
FinchAShawPRosenB. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol2006;100:58–64.
YatesMSMeyerLADeaversMT. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila)2011;4:463–470.